Nothing Special   »   [go: up one dir, main page]

CN114306108A - Nursing agent for balancing gynecological microecological flora structure - Google Patents

Nursing agent for balancing gynecological microecological flora structure Download PDF

Info

Publication number
CN114306108A
CN114306108A CN202210047461.9A CN202210047461A CN114306108A CN 114306108 A CN114306108 A CN 114306108A CN 202210047461 A CN202210047461 A CN 202210047461A CN 114306108 A CN114306108 A CN 114306108A
Authority
CN
China
Prior art keywords
acid
composition
acetic acid
butyric
lactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210047461.9A
Other languages
Chinese (zh)
Inventor
冯慧军
许艳勇
张蕾
李淑华
王琰
金志昊
曹洋
武玮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Turing Weiyan Biotechnology Co ltd
Original Assignee
Beijing Turing Weiyan Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Turing Weiyan Biotechnology Co ltd filed Critical Beijing Turing Weiyan Biotechnology Co ltd
Priority to CN202210047461.9A priority Critical patent/CN114306108A/en
Publication of CN114306108A publication Critical patent/CN114306108A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Cosmetics (AREA)

Abstract

The invention provides a nursing agent for balancing the structure of gynecological microecological flora, which comprises water, a surfactant, a humectant, a preservative and a thickening agent, wherein core functional components comprise a composition of micromolecular organic acid and a composition of saccharides and saccharide derivatives. The nursing agent realizes the obvious sterilization effect on Escherichia coli, staphylococcus aureus and streptococcus agalactiae, has the obvious bacteriostatic effect on Candida albicans, effectively inhibits the growth of harmful bacteria, can also promote the growth of probiotic lactobacillus in the genital tract, and really plays a role in balancing healthy microecological flora.

Description

Nursing agent for balancing gynecological microecological flora structure
Technical Field
The invention relates to the technical field of female nursing agents, in particular to a nursing agent for balancing a gynecological microecological flora structure.
Background
In the vagina of healthy women of child bearing age, lactobacillus is taken as the dominant bacterium, and the acidic substances and the antibacterial substances secreted by the lactobacillus can resist the colonization infection of exogenous pathogenic bacteria, thereby playing an important role in maintaining the normal vaginal micro-ecological environment. When the lactobacilli are reduced and other bacteria are excessively propagated, the imbalance of the vaginal flora is caused. It is commonly known as Aerobic Vaginitis (AV), Bacterial Vaginosis (BV), Trichomonas Vaginitis (TV), vulvovaginal candidiasis (VVC), etc., and serious ascending infection of pathogenic bacteria may also cause Pelvic Inflammatory Disease (PID), endometritis (endometris), Endometriosis (EMS), etc.
Aiming at various infections caused by vaginal microecological disorder, currently, the clinical application mainly adopts external or internal antibiotic medicines, such as clindamycin, cefuroxime, quinolones and the like for treating AV; metronidazole, clindamycin and the like are commonly used for treating BV; clotrimazole, miconazole, nystatin and the like are commonly used for treating VVC, and the antibiotics kill probiotic lactobacillus in the process of killing harmful bacteria, so that the balance of microecological flora is destroyed, and further serious consequences such as relapse and drug resistance are caused.
At present, a plurality of nursing agents or gel products and patents aiming at gynecological infection exist, and related main functional components mainly comprise a broad-spectrum antibacterial disinfectant with a single functional component, such as a chlorine-containing compound (CN103446177A), an antibacterial substance with mixed functional components, such as a traditional Chinese medicine or a traditional Chinese medicine extract (CN101099815A), a plant essence (CN107913397A) and lactobacillus or other bacterial secretion (CN 201110179138.9). The products or components can inhibit the growth of common pathogenic bacteria such as Escherichia coli and staphylococcus aureus, compared with chlorine-containing compounds, although the irritation of the mixed extract of plant sources or probiotic sources to the skin is greatly improved, the problem of poor antibacterial specificity still exists, the mixed extract also has strong inhibiting effect on some self beneficial bacteria such as lactobacillus, and is not beneficial to daily washing and nursing to prevent infection.
Although the influence of lotion on probiotics is concerned, the effect of inhibiting the bacteria of the lotion is weak, the growth of the lactobacilli cannot be really promoted, which is slightly different from the natural situation in the vaginal environment, probably because the exogenous additive component only concerns simple factors such as bacteria inhibition or pH value and the like, the inhibition effect on the vaginal microenvironment and probiotics is caused in the process of inhibiting harmful bacteria, the inhibition effect cannot be really relieved after long-term use, and adverse effects such as low activity of probiotics in the genital tract, fragile vaginal microecology, reduced pathogen resistance and the like are caused.
Disclosure of Invention
The invention mainly solves the problems that most of the existing gynecological lotion or gel core component formulas play a role in inhibiting and killing bacteria aiming at harmful bacteria, the protection and growth promotion effects on the reproductive tract probiotic lactobacillus are neglected, the reproductive tract barrier mainly comprising the lactobacillus cannot be effectively promoted, and the healthy microecological flora cannot be truly balanced.
Based on the problems, the technical scheme provided by the invention is a nursing agent for balancing the structure of gynecological microecological flora, which comprises water, a surfactant, a humectant, a preservative and a thickening agent, wherein the core functional component comprises a composition of small-molecule organic acid and a composition of saccharides and saccharide derivatives.
Wherein the surfactant can be sodium laureth sulfate, tea saponin, coco glucoside, etc., the humectant can be glycerol, sorbitol, aloe extract, etc., the thickener can be sodium carboxymethylcellulose, nonionic guar gum, xanthan gum, etc., and the antiseptic can be sodium benzoate.
The components are as follows by weight: 1.5-5 parts of a small-molecular organic acid composition; 1.5-5 parts of a composition of saccharides and saccharide derivatives; 0-15 parts of a surfactant; 8-10 parts of a humectant; 0.5-1 part of a thickening agent; 0.8-1 part of preservative; 60-88 parts of water.
Wherein the composition of the small molecule organic acid is a combination of at least two of lactic acid, acetic acid, butyric acid or citric acid.
Organic acids, an important class of products for many microorganisms, have mostly been demonstrated to have bacteriostatic effects. At present, the bacteriostatic mechanism of organic acid is yet to be further defined, and it is generally considered that the bacteriostatic mechanism of organic acid has the effects of lowering the pH of the environment, providing an acidic environment, destroying the morphological structure of bacterial cells, and breaking the activity of biochemical metabolic enzyme. The pH affects the dissociation degree of organic acid, which is not easy to dissociate under low pH condition, while non-dissociative acid molecules easily penetrate microbial membrane to dissociate in cells, acidify cytoplasm and cause the death of microbes. The pKa of acetic acid is greater than that of lactic acid, the acetic acid is relatively easier to maintain in a non-dissociative state, the volume of the acetic acid is smaller, the lipid solubility is better, and theoretical bacteriostasis is stronger, but actually, the acetic acid treatment with the acetic acid content of pH4.5 and 0.8M (5% w/v) only inhibits part of BV-related bacteria, which indicates that the inhibition mechanism of lactic acid on bacteria has other aspects, and also indicates that the inhibition mechanisms of different organic acids have differences. In the micro-ecological environment, different organic acid compositions and proportions have different inhibitory effects on conditional pathogenic bacteria.
Further, the composition of the small molecule organic acid in weight percentage is lactic acid (0.1%), acetic acid (0.1%) and butyric acid (0.1%) or lactic acid (0.5%), acetic acid (0.1%) and butyric acid (0.1%), lactic acid (0.5%) and citric acid (0.5%), lactic acid (0.5%), citric acid (0.1%) and butyric acid (0.5%) or lactic acid (0.1%), acetic acid (0.5%) and butyric acid (0.5%) or lactic acid (0.1%), a combination of acetic acid (1%) and butyric acid (1%) or a combination of lactic acid (0.5%), acetic acid (0.5%) and butyric acid (1.5%) or a combination of lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%) and citric acid (0.1%) or a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
Preferably, the composition of the small molecule organic acid in weight percentage is a combination of lactic acid (0.5%), acetic acid (0.5%) and butyric acid (1.5%) or a combination of lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%) and citric acid (0.1%) or a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
More preferably, the composition of the small molecule organic acid in weight percentage is a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
Wherein the composition of the saccharides and saccharide derivatives is a combination of glucose, trehalose and decyl glucoside. Glucose is a main functional substance of organisms, is necessary for the growth of microorganisms, and trehalose is known as 'life sugar' and is a typical stress metabolite formed by the organisms for the change of external environment, so that the organisms are protected against the external severe environment. Exogenous trehalose also has a nonspecific protection effect on organisms, and the part of the organism containing trehalose strongly binds water molecules and has the function of combining water with membrane lipid or replacing membrane-combined water by the trehalose, so that the denaturation of biological membranes and membrane proteins is prevented. The decyl glucoside is catalyzed by glucose, can disperse the combination of lipid and water, prevent the aggregation of saccharide and fatty acid, stabilize protein at low concentration, promote the dispersion of saccharide in flora to a certain extent, and increase the absorbability.
Further, the composition of the small molecular organic acid and the composition of the saccharide and the saccharide derivative are combined according to the weight percentage as follows: lactic acid (0.5%), acetic acid (0.5%), butyric acid (1.5%), glucose (0.5%), trehalose (0.5%) and decyl glucoside (0.1%) or lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%), citric acid (0.1%), glucose (1%), trehalose (1%) and decyl glucoside (0.5%) or lactic acid (1.0%), acetic acid (1.5%), butyric acid (0.5%), glucose (1%), trehalose (1%) and decyl glucoside (0.5%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (1%), trehalose (1%) and decyl glucoside (0.1%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (0.5%), trehalose (1%) and decyl glucoside (0.1%).
Preferably, the composition of the small molecule organic acid and the composition of the saccharide and the saccharide derivative are combined by weight percentage as follows: lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (1%), trehalose (1%) and decyl glucoside (0.1%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (0.5%), trehalose (1%) and decyl glucoside (0.1%).
The core component of the nursing agent is the combination of the small-molecule organic acid composition and the saccharide and saccharide derivative composition, and only after the saccharide and saccharide derivative composition is added into the organic acid composition, the nursing agent can ensure that the lotion can effectively inhibit the growth of harmful bacteria in the urogenital tract and can promote the growth of probiotic lactobacilli in the genital tract, thereby really playing a role in balancing micro-ecological flora.
The following experimental comparisons show that:
1) strain culture: as shown in table 1:
TABLE 1 strains for validation and culture conditions thereof
Bacterial strains Agar plate culture medium Liquid culture medium Culture temperature/. degree.C Cultivation time/h
Escherichia coli Columbia blood plate TSB liquid culture medium 37 24
Staphylococcus aureus Columbia blood plate TSB liquid culture medium 37 24
Streptococcus agalactiae Columbia blood plate TSB liquid culture medium 37 48
Candida albicans Sabouraud agar plate Sabouraud's liquid culture medium 27 48
Lactobacillus crispatus MRS flat plate MRS liquid medium 37 48
2) Preparing a bacterial suspension: freshly cultured single colonies were picked and mixed well in 1mL of 1 XPBS to prepare absorbance OD600The bacterial suspension was 0.5.
3) Preparing a culture medium: MRS liquid medium, TSB liquid medium, and Sabouraud's liquid medium powder were weighed in the reference medium specification, dissolved with water, and sterilized at 115 ℃ for 15 minutes. Respectively utilizing lactic acid, acetic acid, succinic acid, citric acid and butyric acid to regulate the volume ratio content (v/v) of 5 acids in the MRS liquid culture medium, the TSB liquid culture medium and the Sa's liquid culture medium, so that the culture medium contains the multi-component organic acid, and respectively utilizing lactic acid, acetic acid, succinic acid, citric acid, butyric acid, glucose, trehalose and sunflower-based glucoside to regulate the volume ratio content (v/v) of 5 acids and saccharides in the MRS liquid culture medium, the TSB liquid culture medium and the Sa's liquid culture medium, so that the culture medium contains the multi-component organic acid and the saccharides.
4) Culturing: 190. mu.L of liquid medium was added to a 96-well plate, and 10. mu.L of the prepared bacterial suspension was added. Cultured for 48h and placed at OD600The absorbance was measured down, and the test was set up in triplicate, with the negative control being 1 × PBS.
The organic acid compositions are shown in table 2:
TABLE 2 organic acid combinations and ratios
Figure BDA0003472713070000061
The test shows that the 8 organic acid combination formulas B, C, D, F, G, H, I, J play a complete inhibition role on Escherichia coli, staphylococcus aureus, Streptococcus agalactiae and Candida albicans.
The 6 formulas A, B, C, D, E, F have inhibiting effect on lactobacillus crispatus, and the 4 organic acid combined formula G, H, I, J can shorten the time for lactobacillus crispatus to enter logarithmic phase, but after the lactobacillus crispatus enters stationary phase, OD (optical density) is increased600Lower than the negative control, as shown in FIG. 1. Therefore, when only organic acid in the lotion exerts the effect, the inhibition effect on harmful bacteria is influenced by different components and different proportions, and the growth of the harmful bacteria can be inhibited, but the growth of beneficial bacteria cannot be promoted.
Acid combinations H and I were selected for combination with glucose, trehalose and decyl glucoside, respectively, as in table 3:
TABLE 3 acid combinations and different saccharide combinations
Figure BDA0003472713070000071
The acid combination H and I, glucose, trehalose and decyl glucoside play a complete inhibition role in Escherichia coli, staphylococcus aureus, streptococcus agalactiae and candida albicans. The addition of glucose and trehalose has a promoting effect on the growth of lactobacillus crispatus, can shorten the time for lactobacillus crispatus to enter the logarithmic phase, and the addition of sunflower-based glucoside is properly supplemented on the basis of the addition of glucose or glucose and trehalose to effectively increase the number of cells of lactobacillus crispatus in the stationary phase, but the fact that the addition of sunflower-based glucoside alone does not promote the growth of lactobacillus crispatus is found, and the growth promoting effects generated by the sunflower-based glucoside and the sunflower-based glucoside need to be used together, as shown in fig. 2.
The combination of the organic acid composition with the saccharide and saccharide derivative composition is shown in table 3:
TABLE 4 combination of organic acid composition with saccharide and saccharide derivative composition
Figure BDA0003472713070000081
The 5 formulas K, L, M, N, O have complete inhibition effect on Escherichia coli, Staphylococcus aureus, Streptococcus agalactiae and Candida albicans. The combined formula of 5 organic acids and saccharide derivatives can shorten the time for lactobacillus crispatus to enter logarithmic phase. Wherein K, L two combinations have thallus OD after entering stationary phase600Is less negative thanControl, M, N, O thallus OD after stationary phase600Same as the negative control, as shown in FIG. 3. Therefore, when the small-molecule organic acid composition is combined with the saccharide and the saccharide derivative composition to perform a synergistic effect, the effects of inhibiting harmful bacteria and protecting and promoting the growth of beneficial bacteria can be realized.
The invention has the advantages and beneficial effects that: the external care agent obtained by the application utilizes the small molecular organic acid composition and the saccharide and saccharide derivative composition as core effect components, can balance a healthy gynecological micro-ecological flora structure, has an obvious sterilization effect on escherichia coli, staphylococcus aureus and streptococcus agalactiae, effectively inhibits genitourinary and urinary tract harmful bacteria such as escherichia coli, staphylococcus aureus and streptococcus agalactiae, has no obvious sterilization effect on candida albicans but inhibits the active growth of candida albicans, has an obvious bacteriostatic effect, is relatively small in the inhibitory effect on lactic acid bacteria compared with other pathogenic bacteria, and can promote the growth of probiotic lactobacilli in a genital tract by comprehensive use, thereby really playing a role in balancing the micro-ecological flora.
Drawings
FIG. 1 shows the effect of multiple components of organic acids in different ratios on the growth of Lactobacillus crispatus.
FIG. 2 is a graph showing the effect of the combination of organic acids and the combination formula of saccharides and saccharide derivatives of different components on the growth of Lactobacillus crispatus.
FIG. 3 shows the effect of the combination formula of organic acids with different proportions in the same component and saccharides and saccharide derivatives with different proportions in the same component on the growth of Lactobacillus crispatus.
FIG. 4 is a data statistics of the number of Escherichia coli colonies on a plate after 0 to 10 minutes of exposure to the wash formulation.
FIG. 5 is a data statistics of the number of Staphylococcus aureus colonies on the plates after 0 to 20 minutes of exposure to the wash formulation.
FIG. 6 is a data statistics of the number of Streptococcus agalactiae colonies on the plates after 0 to 10 minutes of exposure to the wash formulation.
FIG. 7 is a data set of the number of Candida albicans colonies on the plate after 0 to 60 minutes of exposure to the wash formulation.
FIG. 8 is a data statistics of the number of Lactobacillus crispatus colonies on a plate after 0 to 120 minutes of exposure to the wash formulation.
FIG. 9 is a data statistics of the number of Escherichia coli colonies formed on plates after 0 to 10 minutes of contact with the gel formulation.
FIG. 10 is a data statistics of the number of Staphylococcus aureus colonies on the plates after 0 to 20 minutes of contact with the gel formulation.
FIG. 11 is a data statistics of the number of Streptococcus agalactiae colonies on the plates after 0 to 10 minutes of contact with the gel formulation.
FIG. 12 is a data set of the number of Candida albicans colonies on the plate after 0 to 60 minutes contact with the gel formulation.
FIG. 13 is a data statistics of the number of Lactobacillus crispatus colonies on a plate after 0 to 120 minutes of contact with the gel formulation.
Detailed Description
The technical solution of the present application is described below with reference to the accompanying drawings and specific embodiments.
Example 1 table 1 formula table for washing solution No. 1
Figure BDA0003472713070000101
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 2
Table 2 washing liquid No. 2 formula table
Figure BDA0003472713070000102
Figure BDA0003472713070000111
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 3
Table 3 washing liquid No. 3 formula table
Figure BDA0003472713070000112
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 4
Table 4 washing liquid No. 4 formula table
Figure BDA0003472713070000121
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 5
Table 5 washing liquid No. 5 formula table
Figure BDA0003472713070000122
1) Adding water and sodium laureth sulfate into a main pot, and uniformly stirring; 2) adding pre-dispersed glycerol and xanthan gum into the mixed solution obtained in the step 1), and uniformly stirring; adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 6
Table 6 gel No. 1 formula table
Figure BDA0003472713070000131
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 7
Table 7 gel No. 2 formula table
Figure BDA0003472713070000132
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 8
Table 8 gel No. 3 formula table
Figure BDA0003472713070000141
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 9
Table 9 gel No. 4 formula table
Figure BDA0003472713070000142
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
Example 10
Table 10 gel No. 5 formula table
Figure BDA0003472713070000151
1) Adding water into the main boiler; 2) adding pre-dispersed glycerol and xanthan gum into water, and stirring; 3) adding the acid composition and the composition of the sugar and the saccharide derivatives into the mixed solution obtained in the step 2), and uniformly stirring; 4) adding sodium benzoate into the mixed solution obtained in the step 3), and uniformly stirring.
And selecting a No. 4 lotion product, a No. 5 lotion product, a No. 4 gel product and a No. 5 gel product for testing, wherein the specific operation is that 10 mu L of bacterial suspension is respectively sucked and placed in 90 mu L of undiluted lotion product and gel product, and the bacterial suspension is placed for different times. Treated samples were taken and left for different periods of time, diluted in 1 × PBS solution in a 10-fold gradient, and 100 μ L of the diluted sample was applied to the corresponding solid medium for culturing.
According to experimental data, after the product is contacted with the Escherichia coli for 6 minutes, the magnitude order of the Escherichia coli can be remarkably reduced by 4 magnitude orders, and the product has a remarkable sterilization effect on the Escherichia coli (such as figures 4 and 9); after the staphylococcus aureus is contacted with the staphylococcus aureus for 20 minutes, the number of the staphylococcus aureus can be reduced by one time, and the killing rate of the staphylococcus aureus is close to 50 percent (as shown in figures 5 and 10); after 6 minutes of contact with the streptococcus agalactiae, the magnitude of the streptococcus agalactiae can be reduced by 4 magnitude orders remarkably (such as fig. 6 and 11), and the streptococcus agalactiae has remarkable sterilization effect; after the candida albicans is contacted with the candida albicans for 60 minutes, the active growth of the candida albicans is inhibited, but no obvious bactericidal effect exists, the candida albicans is not remarkably sterilized, and only the bacteriostatic action is realized (as shown in figures 7 and 12). The lotion can still keep the same order of magnitude after instantaneous contact with the lactobacillus crispatus for 0 minute, 30 minutes and 60 minutes, and the lotion formula has no obvious antibacterial effect on the lactobacillus crispatus within 60 minutes of contact with the lactobacillus crispatus (such as figures 8 and 13). Therefore, when the small-molecule organic acid composition is used in combination with the combination of the saccharide and the saccharide derivative composition, the effects of inhibiting both harmful bacteria and protecting and promoting the growth of beneficial bacteria can be achieved.
Although the embodiments of the present invention have been described in detail, the description is only for the preferred embodiments of the present invention and should not be construed as limiting the scope of the present invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.

Claims (9)

1. A nursing agent for balancing gynecological microecological flora structure comprises water, a surfactant, a humectant, a preservative and a thickening agent, and is characterized in that: the core efficacy component comprises a composition of small molecule organic acids and a composition of saccharides and saccharide derivatives.
2. A care agent for balancing the structure of gynaecological microecological flora according to claim 1, characterized in that: the paint comprises the following components in parts by weight: 1.5-5 parts of a small-molecular organic acid composition; 1.5-5 parts of a composition of saccharides and saccharide derivatives; 0-15 parts of a surfactant; 8-10 parts of a humectant; 0.5-1 part of a thickening agent; 0.8-1 part of preservative; 60-88 parts of water.
3. A care agent for balancing the structure of gynaecological microecological flora according to claim 2, characterized in that: the composition of the small molecular organic acid is the combination of at least two of lactic acid, acetic acid, butyric acid or citric acid.
4. A care agent for balancing the structure of gynaecological microecological flora according to claim 3, characterized in that: the composition of the small molecular organic acid in weight percentage is lactic acid (0.1%), acetic acid (0.1%) and butyric acid (0.1%) or lactic acid (0.5%), acetic acid (0.1%) and butyric acid (0.1%), lactic acid (0.5%) and citric acid (0.5%) or lactic acid (0.5%), citric acid (0.1%) and butyric acid (0.5%) or lactic acid (0.1%), acetic acid (0.5%) and butyric acid (0.5%) or lactic acid (0.1%), a combination of acetic acid (1%) and butyric acid (1%) or a combination of lactic acid (0.5%), acetic acid (0.5%) and butyric acid (1.5%) or a combination of lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%) and citric acid (0.1%) or a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
5. A care agent for balancing the structure of gynaecological microecological flora according to claim 4, characterized in that: the composition of the small molecule organic acid is, in weight percentage, a combination of lactic acid (0.5%), acetic acid (0.5%) and butyric acid (1.5%) or a combination of lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%) and citric acid (0.1%) or a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%).
6. A care agent for balancing the structure of gynaecological microecological flora according to claim 5, characterized in that: the composition of the small-molecule organic acid is a combination of lactic acid (1.0%), acetic acid (1.5%) and butyric acid (0.5%) or a combination of lactic acid (1.0%), acetic acid (1%) and butyric acid (1%) in percentage by weight.
7. The nursing agent for balancing gynecological micro-ecological flora structures according to any one of claims 1 to 6, characterized in that: the composition of the saccharides and saccharide derivatives is a combination of glucose, trehalose and decyl glucoside.
8. A care agent for balancing the structure of gynaecological microecological flora according to claim 7, characterized in that: the composition of the small molecular organic acid and the composition of the saccharide and the saccharide derivative are combined according to the weight percentage as follows: lactic acid (0.5%), acetic acid (0.5%), butyric acid (1.5%), glucose (0.5%), trehalose (0.5%) and decyl glucoside (0.1%) or lactic acid (0.5%), acetic acid (0.5%), butyric acid (1%), citric acid (0.1%), glucose (1%), trehalose (1%) and decyl glucoside (0.5%) or lactic acid (1.0%), acetic acid (1.5%), butyric acid (0.5%), glucose (1%), trehalose (1%) and decyl glucoside (0.5%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (1%), trehalose (1%) and decyl glucoside (0.1%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (0.5%), trehalose (1%) and decyl glucoside (0.1%).
9. A care agent for balancing the structure of gynaecological microecological flora according to claim 8, characterized in that: the composition of the small molecular organic acid and the composition of the saccharide and the saccharide derivative are combined according to the weight percentage as follows: lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (1%), trehalose (1%) and decyl glucoside (0.1%) or lactic acid (1.0%), acetic acid (1%), butyric acid (1%), glucose (0.5%), trehalose (1%) and decyl glucoside (0.1%).
CN202210047461.9A 2022-01-17 2022-01-17 Nursing agent for balancing gynecological microecological flora structure Pending CN114306108A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210047461.9A CN114306108A (en) 2022-01-17 2022-01-17 Nursing agent for balancing gynecological microecological flora structure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210047461.9A CN114306108A (en) 2022-01-17 2022-01-17 Nursing agent for balancing gynecological microecological flora structure

Publications (1)

Publication Number Publication Date
CN114306108A true CN114306108A (en) 2022-04-12

Family

ID=81028349

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210047461.9A Pending CN114306108A (en) 2022-01-17 2022-01-17 Nursing agent for balancing gynecological microecological flora structure

Country Status (1)

Country Link
CN (1) CN114306108A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796173A (en) * 2022-04-25 2022-07-29 上海森梅维斯药业有限公司 Composition for regulating vaginal microecology by inhibiting vaginal harmful bacteria and protecting lactobacillus by using lactic acid and nursing method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193428A1 (en) * 2005-04-27 2008-08-14 Shenzhen Phlora Biotechnology Limited Composition and Method for Modulating and Maintaining Vaginal Bacterial Flora and Vaginal Acidity
CN106689671A (en) * 2016-12-28 2017-05-24 新昌县赛因斯生物科技有限公司 Biological bacterium-containing livestock feed and preparation method thereof
CN109288793A (en) * 2018-07-27 2019-02-01 江苏中天药业有限公司 A kind of spray and preparation method thereof adjusted for vagina pH environment
US20190231748A1 (en) * 2016-10-09 2019-08-01 Shenzhen Eulikan Biotechnology Co., Ltd. Composition for vagina and antimicrobial agent combination for use in preparing composition for vagina
CN112773780A (en) * 2019-11-11 2021-05-11 深圳优丽康生物技术有限公司 Composition for vagina and vulva and application thereof
CN112933109A (en) * 2021-02-03 2021-06-11 湖南奥朗特医疗器械有限公司 Vagina pH regulator and preparation method and application thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080193428A1 (en) * 2005-04-27 2008-08-14 Shenzhen Phlora Biotechnology Limited Composition and Method for Modulating and Maintaining Vaginal Bacterial Flora and Vaginal Acidity
US20190231748A1 (en) * 2016-10-09 2019-08-01 Shenzhen Eulikan Biotechnology Co., Ltd. Composition for vagina and antimicrobial agent combination for use in preparing composition for vagina
CN106689671A (en) * 2016-12-28 2017-05-24 新昌县赛因斯生物科技有限公司 Biological bacterium-containing livestock feed and preparation method thereof
CN109288793A (en) * 2018-07-27 2019-02-01 江苏中天药业有限公司 A kind of spray and preparation method thereof adjusted for vagina pH environment
CN112773780A (en) * 2019-11-11 2021-05-11 深圳优丽康生物技术有限公司 Composition for vagina and vulva and application thereof
CN112933109A (en) * 2021-02-03 2021-06-11 湖南奥朗特医疗器械有限公司 Vagina pH regulator and preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
余㵑等: "医学微生物学", 人民卫生出版社, pages: 190 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796173A (en) * 2022-04-25 2022-07-29 上海森梅维斯药业有限公司 Composition for regulating vaginal microecology by inhibiting vaginal harmful bacteria and protecting lactobacillus by using lactic acid and nursing method

Similar Documents

Publication Publication Date Title
EP3520785B1 (en) Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use
CN105189733B (en) Method for producing partially purified extracellular metabolites from bacillus coagulans and biological applications thereof
TWI405577B (en) Antimicrobial agent
Guiot et al. Partial antibiotic decontamination.
KR101287126B1 (en) Pharmaceutical compositon prevention and treatment of vaginitis and urinary tract infection comprising fermented solution of plant-originated Lactic acid bacteria
CN103409334B (en) Inhibit the Bacillus acidi lactici and application thereof of vaginitis pathogen
EP3548045B1 (en) Compositions for use in the treatment of urogenital infections
KR101720145B1 (en) Cosmetic composition for prevention and improvement of vaginosis
CN111084831A (en) Bacteriostatic composition for inhibiting vaginal pathogenic bacteria and application thereof
CN114306108A (en) Nursing agent for balancing gynecological microecological flora structure
CN111588723B (en) Gynecological disinfectant and preparation method thereof
CH651205A5 (en) COMPOSITION FOR FEMALE INTIMATE HYGIENE, PARTICULARLY FOR VAGINAL LAVENDERS.
EP3658131B1 (en) Composition for the treatment of bacterial vaginosis
EP1481666B1 (en) A composition for re-establishment of the vaginal ecosystem
KR20030037094A (en) Antibiotic compositions comprising plant extract
CN115369061A (en) Selective helicobacter pylori culture medium and preparation method thereof
RU2367454C1 (en) Intime hygiene product "femivit"
CN115837068B (en) Application of sodium surfactin, composition and application method thereof
KR20150075447A (en) Cosmetic composition for prevention and improvement of vaginosis
CN116784446B (en) Composition for synergistically inhibiting pseudomonas aeruginosa and application thereof
CN106902116A (en) A kind of new opplication of rifamycin quinolizine ketone dual-target molecule
KR102430080B1 (en) Antibacterial composition comprising methyl gallate and tylosin
CN118236395A (en) Private protection antibacterial liquid and preparation method thereof
JP2018002661A (en) Antibacterial antiseptic composition and composition prepared therewith
Al-Naama Evaluation of inhibitory effect of honey on some bacterial isolates

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220412

RJ01 Rejection of invention patent application after publication